390 related articles for article (PubMed ID: 37934320)
1. The possible place for psychedelics in pharmacotherapy of mental disorders.
Wojtas A
Pharmacol Rep; 2023 Dec; 75(6):1313-1325. PubMed ID: 37934320
[TBL] [Abstract][Full Text] [Related]
2. [Contribution of serotonin 5-HT
Ibi D
Nihon Yakurigaku Zasshi; 2023 May; 158(3):229-232. PubMed ID: 36990794
[TBL] [Abstract][Full Text] [Related]
3. Hallucinogenic/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: Evidence and mechanisms of action.
Dos Santos RG; Hallak JE; Baker G; Dursun S
J Psychopharmacol; 2021 Apr; 35(4):453-458. PubMed ID: 33740877
[TBL] [Abstract][Full Text] [Related]
4. New investigational agents for the treatment of major depressive disorder.
Pochwat B; Krupa AJ; Siwek M; Szewczyk B
Expert Opin Investig Drugs; 2022 Oct; 31(10):1053-1066. PubMed ID: 35975761
[TBL] [Abstract][Full Text] [Related]
5. Role of Psychedelics in Treatment-Resistant Depression.
Kamal S; Jha MK; Radhakrishnan R
Psychiatr Clin North Am; 2023 Jun; 46(2):291-305. PubMed ID: 37149346
[TBL] [Abstract][Full Text] [Related]
6. Antidepressant-like effects of psychedelics in a chronic despair mouse model: is the 5-HT
Sekssaoui M; Bockaert J; Marin P; Bécamel C
Neuropsychopharmacology; 2024 Mar; 49(4):747-756. PubMed ID: 38212441
[TBL] [Abstract][Full Text] [Related]
7. Psychedelics for treatment resistant depression: are they game changers?
Kalfas M; Taylor RH; Tsapekos D; Young AH
Expert Opin Pharmacother; 2023; 24(18):2117-2132. PubMed ID: 37947195
[TBL] [Abstract][Full Text] [Related]
8. Psychedelics, but Not Ketamine, Produce Persistent Antidepressant-like Effects in a Rodent Experimental System for the Study of Depression.
Hibicke M; Landry AN; Kramer HM; Talman ZK; Nichols CD
ACS Chem Neurosci; 2020 Mar; 11(6):864-871. PubMed ID: 32133835
[TBL] [Abstract][Full Text] [Related]
9. Interaction of hallucinogenic rapid-acting antidepressants with mGlu2/3 receptor ligands as a window for more effective therapies.
Chruścicka-Smaga B; Machaczka A; Szewczyk B; Pilc A
Pharmacol Rep; 2023 Dec; 75(6):1341-1349. PubMed ID: 37932583
[TBL] [Abstract][Full Text] [Related]
10. Spectral signatures of serotonergic psychedelics and glutamatergic dissociatives.
Pallavicini C; Vilas MG; Villarreal M; Zamberlan F; Muthukumaraswamy S; Nutt D; Carhart-Harris R; Tagliazucchi E
Neuroimage; 2019 Oct; 200():281-291. PubMed ID: 31247301
[TBL] [Abstract][Full Text] [Related]
11. Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.
Lowe H; Toyang N; Steele B; Grant J; Ali A; Gordon L; Ngwa W
Molecules; 2022 Apr; 27(8):. PubMed ID: 35458717
[TBL] [Abstract][Full Text] [Related]
12. [Neurotrophic mechanisms of psychedelic therapy].
Corne R; Mongeau R
Biol Aujourdhui; 2019; 213(3-4):121-129. PubMed ID: 31829932
[TBL] [Abstract][Full Text] [Related]
13. [Up-to-Date on clinical and preclinical studies of psilocybin therapy].
Ibi D
Nihon Yakurigaku Zasshi; 2024; 159(4):214-218. PubMed ID: 38945903
[TBL] [Abstract][Full Text] [Related]
14. [Ketamine, psilocybin, and rapid acting antidepressant: new promise for psychiatry?].
Bottemanne H; Claret A; Fossati P
Encephale; 2021 Apr; 47(2):171-178. PubMed ID: 33190819
[TBL] [Abstract][Full Text] [Related]
15. Molecular mechanisms of rapid-acting antidepressants: New perspectives for developing antidepressants.
Chen T; Cheng L; Ma J; Yuan J; Pi C; Xiong L; Chen J; Liu H; Tang J; Zhong Y; Zhang X; Liu Z; Zuo Y; Shen H; Wei Y; Zhao L
Pharmacol Res; 2023 Aug; 194():106837. PubMed ID: 37379962
[TBL] [Abstract][Full Text] [Related]
16. d-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: Mechanism of action and potential therapeutic applications in mood disorders.
De Gregorio D; Enns JP; Nuñez NA; Posa L; Gobbi G
Prog Brain Res; 2018; 242():69-96. PubMed ID: 30471683
[TBL] [Abstract][Full Text] [Related]
17. Esketamine and Psilocybin-The Comparison of Two Mind-Altering Agents in Depression Treatment: Systematic Review.
Psiuk D; Nowak EM; Dycha N; Łopuszańska U; Kurzepa J; Samardakiewicz M
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232748
[TBL] [Abstract][Full Text] [Related]
18. The promises and perils of psychedelic pharmacology for psychiatry.
McClure-Begley TD; Roth BL
Nat Rev Drug Discov; 2022 Jun; 21(6):463-473. PubMed ID: 35301459
[TBL] [Abstract][Full Text] [Related]
19. Classic Psychedelics in Addiction Treatment: The Case for Psilocybin in Tobacco Smoking Cessation.
Johnson MW
Curr Top Behav Neurosci; 2022; 56():213-227. PubMed ID: 35704271
[TBL] [Abstract][Full Text] [Related]
20. Structural pharmacology and therapeutic potential of 5-methoxytryptamines.
Warren AL; Lankri D; Cunningham MJ; Serrano IC; Parise LF; Kruegel AC; Duggan P; Zilberg G; Capper MJ; Havel V; Russo SJ; Sames D; Wacker D
Nature; 2024 Jun; 630(8015):237-246. PubMed ID: 38720072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
